BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the ...

Bristol Myers Squibb (NYSE: BMY) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

Bristol Myers Squibb's rally from the July 2024 bottom is well deserved as the market rotated from high growth to high dividend-yielding sectors. Learn more on BMY stock here.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Discover Bristol-Myers Squibb's groundbreaking patent for personalized SLE treatment, utilizing IKZF3 gene expression to optimize dosage for better patient outcomes.

For those with $200 to spare that isn't being saved for emergencies, let's consider two healthcare stocks within that budget ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Laura Foran's late husband, Gerry, had a desk plaque that said, "I'm kind of a big deal." The 47-year-old Allentown woman is ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) on September 6 and set a price ...